Список литературы

1. Van der Post R.S., Vogelaar I.P., Carneiro F. et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52(6): 361 - 74.

2. Petrovchich I., Ford JM. Genetic predisposition to gastric cancer. SeminOncol 2016; 43(5): 554 - 9.

3. Поддубная И.В., Каприн А.Д., Лядов В.К. Классификация опухолей TNM. 8-я ред. Руководство и атлас. Т. I: Опухоли торакоабдоминальной локализации. М.; Практическая медицина, 2018. - 424 с.

4. F. Lordick, F. Carneiro, S. Cascinu, T. Fleitas, K. Haustermans, G. Piessen, A. Vogel & E.C. Smyth13, on behalf of the ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Available online 29 July 2022. https://www.annalsofoncology.org/article/S0923-7534(22)01851-8/fulltext#relatedArticles

5. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesРисунок 33) Gastric Cancer Version 3.25 - August 22, 2025. Доступно на https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf

6. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: LOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229 - 263. doi: 10.3322/caac.21834

7. Каприн А.Д., Старинский В.В., Шахзадова А.О. (eds.): Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2024. - 276 с.

8. Fukayama M., Rugge M., Washington M.K. Tumours of the stomach. In: WHO Classification of Tumours Editorial Board. Digestive Tumours. Lyon (France): IARC 2019; 59 - 109.

9. Association, Japanese Gastric Cancer. "Japanese classification of gastric carcinoma: 3rd English edition." Gastric Cancer 14 (2011): 101 - 112.

10. Wanebo H.J., Kennedy B.J., Chmiel J. et al. Cancer of the stomach. A patient care study by the American College of Surgeons. AnnSurg 1993; 218(5): 583.

11. Щепотин И.Б., Эванс С.Р. Рак желудка: практическое руководство по профилактике, диагностике и лечению. Киев; "Книга Плюс", 2000. - 227 с.

12. Березов Ю.Е. Хирургия рака желудка. М.; Медицина, 1976 г. - 352 с.

13. Русанов А.А. Рак желудка. М.; Медицина, 1979. - 180 с.

14. Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: Clinical nutrition in cancer.//Clin Nutr. 2021; 40(5): 2898 - 2913. doi: 10.1016/j.clnu.2021.02.005

15. Lordick F, Al-Batran SE, Arnold D, Borner M, Bruns CJ, Eisterer W, Faber G, Gockel I, Рисунок 34 D, Lorenzen S, Рисунок 35 M, Pritzkuleit R, Stahl M, Thuss-Patience P, Рисунок 36 E, Zander T, Maschmeyer G; German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer. 2024 Jan; 27(1): 6 - 18. doi: 10.1007/s10120-023-01424-y. Epub 2023 Oct 17. PMID: 37847333; PMCID: PMC10761449

16. MatsumotoY., YanaiH., TokiyamaH. etal. Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer. J Gastroenterol 2000; 35(5): 326 - 31.

17. Cardoso R., Coburn N., Seevaratnam R. et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer 2012; 15 (Suppl 1): S19 - 26. 152 Watt I. et al.

18. Spolverato G., Ejaz A., Kim Y. et al. Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative. J Am Coll Surg 2015; 220(1): 48 - 56.

19. MurataY., SuzukiS., OgumaH. etal. Recent progress in staging gastric cancer by endoscopic ultrasonography. Proceeding of 3rd International Gastric Cancer Congress, Seoul, Korea, 1999.

20. Watt I. et al. Laparoscopy, ultrasound and computed tomography in cancer of the oesophagus and gastric cardia: a prospective comparison for detecting intra abdominal metastases. British journal of surgery. - 1989. - Т. 76. - N. 10. - С. 1036 - 1039.

21. Chen C.Y., Hsu J.S., Wu D.C. et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT-correlation with surgical and histopathologic results. Radiology 2007; 242: 472 - 82.

22. Fukuya T., Honda H., Kaneko K. et al. Efficacy of helical CT in T staging of gastric cancer. J Comput Assist Tomography 1997; (21): 73 - 81.

23. Takao M., Fukuda T., Iwanaga S. et al. Gastric cancer: evaluation of triphasic spiral CT and radiologic-pathologic correlation. J Comput Assist Tomography 1998; (22): 288 - 94.

24. Kong J.H. et al. Lung metastases in metastatic gastric cancer: pattern of lung metastases and clinical outcome//Gastric Cancer. - 2012. - Т. 15. - N. 3. - С. 292 - 298.

25. Liao S.R. et al. Transabdominal ultrasonography in preoperative staging of gastric cancer//World Journal of Gastroenterology: WJG. - 2004. - Т. 10. - N. 23. - С. 3399.

26. Karanicolas P.J., Elkin E.B., Jacks L.M. et al. Staging Laparoscopy in the Management of Gastric Cancer: A Population-Based Analysis. J Am Coll Surg 2011; 213: 644 - 51.

27. Leake P.A., Cardoso R., Seevaratnam R. et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 2012; 15 (Suppl. 1): S27 - 37.

28. Leake P.A., Cardoso R., Seevaratnam R. et al. A systematic review of the accuracy and indications for diagnostic laparoscopy before curative-intent resection of gastric cancer. Gastric Cancer 2012; 15 (Suppl. 1): S38 - 47.

29. Mezhir J.J., Shah M.A., Jacks L.M. et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. AnnSurgOncol 2010; 17(12): 3173 - 80. doi: 10.1245/s10434-010-1183-0.

30. Sarela A.I., Lefkowitz R., Brennan M.F. et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg 2006; 191(1): 134 - 8.

31. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005; 2(1): 3. Published 2005 Feb 8. doi: 10.1186/1477-7800-2-3.

32. Van Vliet EP, van der Lugt A, Kuipers EJ et al. Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol. 2007 Sep 1; 96(3): 200 - 6.

33. Lim J.S., Yun M.J., Kim M.J. et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 2006; 26(1): 143 - 56.

34. Dassen A.E., Lips D.J., Hoekstra C.J. et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol. 2009; 35(5): 449 - 55. doi: 10.1016/j.ejso. 2008.11.010.

35. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer (2003) 98(7): 1521 - 3010.

36. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994; 73: 2680 - 6.

37. Novelli MR. Dataset for the histopathological reporting of gastric carcinoma (2nd edition). The Royal College of Pathologists. 2007: 1 - 15.

38. Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of malignant tumours. Eighth edition. - 2019: 63.

39. Bartley A.N., Washington M.K., Colasacco C. et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society of Clinical Pathology, and American Society of Clinical Oncology. J Clin Oncol 2017; 35(4): 446 - 64.

40. Raskin GA, Mukhina MS, Kaurtseva AS, Andreeva YuYu, Zavalishina LE, Protasova AE, Orlova RV. Microsatellite instability and DNA mismatch repair deficiency detection in tumors of various sites. Russian Journal of Archive of Pathology. 2023; 85(1): 36 - 42. (In Russ.) https://doi.org/10.17116/patol20238501136

41. Le D.T., Uram J.N., Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509 - 20.

42. Pimentel-Nunes P., Dinis-Ribeiro M., Ponchon T. et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2015; 47: 829 - 54.

43. Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023 Jan; 26(1): 1 - 25. doi: 10.1007/s10120-022-01331-8. Epub 2022 Nov 7. PMID: 36342574; PMCID: PMC9813208.

44. Adachi Y., Kamakura T., Mori M. et al. Prognostic significance of the number of positive lymph nodes in gastric carcinoma. Br J Surg 1994; 81: 414 - 6.

45. Ito H., Oohata Y., Nakamura K. et al. Complete ten-year postgastrectomy follow-up of early gastric cancer. Am J Surg 1989; 158: 14 - 16.

46. Isozaki H., Okajima K., Ichinowa T. et al. Distant lymph node metastasis of early gastric cancer. Jpn J Surg 1997; 27: 600 - 5.

47. Hasuike N, Ono H, Boku N, et al. A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer. 2018; 21(1): 114 - 23.

48. Takizawa K., Ono H., Hasuike N. et al. A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010). Gastric Cancer 24, 479 - 491 (2021). https://doi.org/10.1007/s10120-020-01134-9.

49. Малихова, Кашин, Murakami T. Pathomorphological diagnosis. Definition and gross classification of early gastric cancer. Gann Monogr Cancer Research 1971; 11: 53 - 55.

50. Yang L, Qi J, Chen W, Guo Q, Xie R, Zhao Z, Qin S, Liu A, Den M, Fan C, Bai J, Lin H, Guo H, Yang S. Low-dose PPI to prevent bleeding after ESD: A multicenter randomized controlled study. Biomed Pharmacother. 2021 Apr; 136: 111251. doi: 10.1016/j.biopha.2021.111251. Epub 2021 Jan 12. PMID: 33450486.

51. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021 Jan; 24(1): 1 - 21. doi: 10.1007/s10120-020-01042.

52. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113 - 123.

53. Давыдов М.И., Туркин И.Н., Полоцкий Б.Е., Стилиди И.С. и др. Результаты хирургии раннего рака желудка. Материалы заседания Московского онкологического общества N 550 25.09.2008.

54. Probst A, Pommer B, Golger D et al. Endoscopic submucosal dissection in gastric neoplasia - experience from a European center. Endoscopy 2010; 42: 1037 - 1044.

55. Choi J, Kim SG, Im JP et al. Endoscopic prediction of tumor invasion depth in early gastric cancer. Gastrointest Endosc 2011; 73: 917 - 927.

56. Pimentel-Nunes Pedro et al. Endoscopic submucosal dissection: ESGE Guideline. Endoscopy 2015; 47: 829 - 854 DOI http://dx.doi.org/10.1055/s-0034-1392882.

57. Goto O, Takeuchi H, Kitagawa Y, Yahagi N. Hybrid surgery for early gastric cancer. Transl Gastroenterol Hepatol. 2016; 1: 26. Published 2016 Apr 6. doi: 10.21037/tgh.2016.03.23.

58. Kitakata H, Itoh T, Kinami S, et al. Sealed endoscopic full-thickness resection for gastric cancer: a pilot study in an ex vivo and in vivo porcine model. Endosc Int Open. 2019; 7(1): E36 - E42. doi: 10.1055/a-0777-1954.

59. Hiki N, Nunobe S. Laparoscopic endoscopic cooperative surgery (LECS) for the gastrointestinal tract: Updated indications. Ann Gastroenterol Surg. 2019 Feb 19; 3(3): 239 - 246. doi: 10.1002/ags3.12238. PMID: 31131352; PMCID: PMC6524076.

60. Kashin S, Kraynova E, Merkulova A et al. eP83 A Comparison Of Endoscopic Submucosal Dissection (Esd), Laparoscopic Endoscopic Cooperative Surgery (Lecs) And Open Surgery For Early Gastric Cancer (Egc): A Retrospective Study. Endoscopy 2021; 53: S123.

61. Kim TH, Kim IH, Kang SJ, Choi M, Kim BH, Eom BW, Kim BJ, Min BH, Choi CI, Shin CM, Tae CH, Gong CS, Kim DJ, Cho AE, Gong EJ, Song GJ, Im HS, Ahn HS, Lim H, Kim HD, Kim JJ, Yu JI, Lee JW, Park JY, Kim JH, Song KD, Jung M, Jung MR, Son SY, Park SH, Kim SJ, Lee SH, Kim TY, Bae WK, Koom WS, Jee Y, Kim YM, Kwak Y, Park YS, Han HS, Nam SY, Kong SH; Development Working Groups for the Korean Practice Guidelines for Gastric Cancer 2022 Task Force Team. Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. J Gastric Cancer. 2023 Jan; 23(1): 3 - 106. doi: 10.5230/jgc.2023.23.e11. Erratum in: J Gastric Cancer. 2023 Apr; 23(2): 365 - 373. doi: 10.5230/jgc.2023.23.e20. PMID: 36750993; PMCID: PMC9911619

62. Kim W., Kim H.H., Han S.U. et al. Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). AnnSurg 2016; 263(1): 28 - 35.

63. Давыдов М.И., Тер-Ованесов М.Д., Полоцкий Б.Е. и др. Рак желудка. В кн.: Энциклопедия клинической онкологии: М.И. Давыдов (ed.). М.; РЛС, 2004. - С. 223 - 30.

64. Давыдов М.И., Туркин И.Н., Давыдов М.М. Энциклопедия хирургии рака желудка: Давыдов М.И. (ed.). М.; Эксмо, 2011. - С. 536.

65. Стилиди И.С., Неред С.Н. Современные представления об основных принципах хирургического лечения местно-распространенного рака желудка. Практическая онкология, 2009; 10(1): 20 - 7.

66. Hu Y., Huang C., Sun Y. etal. Laparoscopic D2 subtotal gastrectomy versus conventional open surgery for advanced gastric cancer: The safety analysis from a multicenter prospective randomized controlled trial in China (CLASS-01 trial). J Clin Oncol 2015; 33: 3_suppl. 122 - 22. DOI: 10.1200/jco.2015.33.3_suppl.122.

67. Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, Ito S, Kurita A, Mizusawa J, Nakamura K; Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg. 2015 Mar; 102(4): 341 - 8. doi: 10.1002/bjs.9764. Epub 2015 Jan 21. PMID: 25605628.

68. Quan Y., Huang A., Ye M. et al. Comparison of laparoscopic versus open gastrectomy for advanced gastric cancer: an updated meta-analysis. Gastric Cancer 2016; 19: 939 - 50.

69. Lee J.H., Nam B.H., Ryu K.W. et al. Comparison of outcomes after laparoscopy-assisted and open total gastrectomy for early gastric cancer. Br J Surg 2015; 102: 1500 - 5.

70. Lee H.J., Hyung W.J., Yang H.K. et al. Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). Ann Surg 2019; 9. doi: 10.1097/SLA.0000000000003217.

71. Lee S.W., EtohT., OhyamaT. etal. Short-term outcomes from a multi-institutional, phase III study of laparoscopic versus open distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). J Clin Oncol 35; 15_suppl: 4029 - 29. DOI: 10.1200/JCO.2017.35.15_suppl.4029.

72. Katai H, Mizusawa J, Katayama H, Kunisaki C, Sakuramoto S, Inaki N, et al. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer. 2019; 22(5): 999 - 1008.

73. The 94th Annual Meeting of the Japanese gastric cancer association congress. PS2 Efficacy of Japanese gastric cancer treatment guidelines (ver. 6)

74. Jiang Yu, Changming Huang, Yihong Sun, Xiangqian Su, Hui Cao, Jiankun Hu, Kuan Wang, Jian Suo, Kaixiong Tao, Xianli He, Hongbo Wei, Mingang Ying, Weiguo Hu, Xiaohui Du, Yanfeng Hu, Hao Liu, Chaohui Zheng, Ping Li, Jianwei Xie, Fenglin Liu, Ziyu Li, Gang Zhao, Kun Yang, Chunxiao Liu, Haojie Li, Pingyan Chen, Jiafu Ji, Guoxin Li, Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group//Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial//JAMA. 2019 May 28; 321(20): 1983 - 1992. doi: 10.1001/jama.2019.5359. PMID: 31135850. PMCID: PMC6547120.

75. Hoon Hur, Hyun Yong Lee, Hyuk-Joon Lee, Min Chan Kim, Woo Jin Hyung, Young Kyu Park, Wook Kim, Sang-Uk Han//Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial//BMC Cancer. 2015 May 5; 15: 355. doi: 10.1186/s12885-015-1365-z. PMID: 25939684. PMCID: PMC4432816.

76. Leonie Haverkamp, Hylke JF Brenkman, Maarten FJ Seesing, Suzanne S Gisbertz, Mark Ivan Berge Henegouwen, Misha DP Luyer, Grard AP Nieuwenhuijzen, Bas PL Wijnhoven, Jan JB van Lanschot, Wobbe O de Steur, Henk H Hartgrink, Jan HMB Stoot, Karel WE Рисунок 37, Ernst J Spillenaar Bilgen, Jeroen E Рисунок 38, Ewout A Kouwenhoven, Marc J van Det, Donald L van der Peet, Freek Daams, Werner A Draaisma, Ivo AMJ Broeders, Henk F van Stel, Miangela M Lacle, Jelle P Ruurda, Richard van Hillegersberg, LOGICA study group//Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial)//BMC Cancer. 2015 Jul 29; 15: 556. doi: 10.1186/s12885-015-1551-z. PMID: 2621967. PMCID: PMC4518687.

77. Yu J. et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial//Jama. - 2019. - Т. 321. - N. 20. - С. 1983 - 1992.

78. Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021 Aug; 41(8): 747 - 795. doi: 10.1002/cac2.12193. Epub 2021 Jul 1. PMID: 34197702; PMCID: PMC8360643.

79. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer. 2019 Mar; 19(1): 1 - 48. doi: 10.5230/jgc.2019.19.e8. Epub 2019 Mar 19. Erratum in: J Gastric Cancer. 2019 Sep; 19(3): 372 - 373. PMID: 30944757; PMCID: PMC6441770.

80. Zhou J, Du R, Zhang Q, Wang D. Laparoscopy-assisted pylorus-preserving gastrectomy versus laparoscopy-assisted distal gastrectomy for early gastric cancer in perioperative outcomes: A meta-analysis. Asian J Surg. 2020 Aug; 43(8): 862 - 863. doi: 10.1016/j.asjsur.2020.05.009. Epub 2020 Jun 8. PMID: 32527581.

81. Nunobe S, Hiki N. Function-preserving surgery for gastric cancer: current status and future perspectives. Transl Gastroenterol Hepatol. 2017 Sep 25; 2: 77. doi: 10.21037/tgh.2017.09.07. PMID: 29034350; PMCID: PMC5639020.

82. Huang C, Yu F, Zhao G, Xia X. Postoperative quality of life after laparoscopy-assisted pylorus-preserving gastrectomy compared with laparoscopy-assisted distal gastrectomy for early gastric cancer. J Gastroenterol Hepatol. 2020 Oct; 35(10): 1712 - 1719. doi: 10.1111/jgh.14985. Epub 2020 Feb 11. PMID: 31945189.

83. Shiraishi T. et al. Totally Laparoscopic Total Gastrectomy with Transvaginal Specimen Extraction in Gastric Cancer: A Report of 4 Cases//The Kitakanto Medical Journal.. - 2016. - Т. 66. - N. 2. - С. 159 - 162.

84. Schmidt B, Yoon SS. D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol. 2013 Mar; 107(3): 259 - 64. doi: 10.1002/jso.23127. Epub 2012 Apr 18. PMID: 22513454; PMCID: PMC3807123.

85. Songun I., Putter H., Kranenbarg E.M. et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11(5): 439 - 49. doi: 10.1016/S1470-2045(10)70070-X.

86. Sasako M., Sano T., Yamamoto S. et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359(5): 453.

87. Liang Y, Wu L, Wang X, Ding X, Liu H, Li B, Wang B, Pan Y, Zhang R, Liu N, Liang H. Positive impact of adding No. 14v lymph node to D2 dissection on survival for distal gastric cancer patients after surgery with curative intent. Chin J Cancer Res. 2015 Dec; 27(6): 580 - 7. doi: 10.3978/j.issn.1000-9604.2015.12.02. PMID: 26752932; PMCID: PMC4697099.

88. Sano T., Sasako M., Mizusawa J. et al Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg 2017; 265(2): 277 - 83. doi: 10.1097/SLA.0000000000001814.

89. Yu W., Choi G.S., Chung H.Y. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006; 93(5): 559 - 63.

90. Kurokawa Y, Doki Y, Mizusawa J, Terashima M, Katai H, Yoshikawa T, Kimura Y, Takiguchi S, Nishida Y, Fukushima N, Iwasaki Y, Kaji M, Hirao M, Katayama H, Sasako M. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018 Jul; 3(7): 460 - 468. doi: 10.1016/S2468-1253(18)30090-6. Epub 2018 Apr 28. PMID: 29709558.

91. Jongerius EJ, Boerma D, Seldenrijk KA, Meijer SL, Scheepers JJ, Smedts F, Lagarde SM, Balague Ponz O, van Berge Henegouwen MI, van Sandick JW, Gisbertz SS. Role of omentectomy as part of radical surgery for gastric cancer (OMEGA Trial). Br J Surg. 2016 Oct; 103(11): 1497 - 503. doi: 10.1002/bjs.10149. Epub 2016 Aug 23. PMID: 27550526.

92. Chai SW, Wang SH, Wang CY, Chen YC, Soong RS, Huang TS. Partial Versus Total Omentectomy in Patients with Gastric Cancer: A Systemic Review and Meta-Analysis. Cancers (Basel). 2021 Oct 3; 13(19): 4971. doi: 10.3390/cancers13194971. PMID: 34638455; PMCID: PMC8508137.

93. Ri M, Nunobe S, Honda M, Akimoto E, Kinoshita T, Hori S, Aizawa M, Yabusaki H, Isobe Y, Kawakubo H, Abe T. Gastrectomy with or without omentectomy for cT3-4 gastric cancer: a multicentre cohort study. Br J Surg. 2020 Nov; 107(12): 1640 - 1647. doi: 10.1002/bjs.11702. Epub 2020 May 20. PMID: 32430907.

94. Jung DH, Lee Y, Kim DW, Park YS, Ahn SH, Park DJ, Kim HH. Laparoscopic proximal gastrectomy with double tract reconstruction is superior to laparoscopic total gastrectomy for proximal early gastric cancer. Surg Endosc. 2017 Oct; 31(10): 3961 - 3969. doi: 10.1007/s00464-017-5429-9. Epub 2017 Mar 24. PMID: 28342130.

95. Осминин С.В., Комаров Р.Н., Иванов Д.Л. Методы реконструкции желудочно-кишечного тракта после гастрэктомии по поводу рака желудка. Экспериментальная и клиническая гастроэнтерология. 2020; 184(12): 68 - 75. DOI: 10.31146/1682-8658-ecg-184-12-68-75.

96. Li Z, Shan F, Ying X, Zhang Y, E J-E, Wang Y, et al. Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial. JAMA Surg. 2019; 154(12): 1093 - 1101.

97. Kitagami H. et al. Technique of Roux-en-Y reconstruction using overlap method after laparoscopic total gastrectomy for gastric cancer: 100 consecutively successful cases//Surgical endoscopy. - 2016. - Т. 30. - N. 9. - С. 4086 - 4091.

98. Tomita R., Tanjoh K., Fujisaki S. Total gastrectomy reconstructed by interposition of a jejunal J pouch with preservation of hepatic vagus branch and lower esophageal sphincter for T2 gastric cancer without lymph node metastasis//Hepato-gastroenterology. - 2004. - Т. 51. - N. 58. - С. 1233 - 1240.

99. Li S. et al. A meta-analysis of comparison of proximal gastrectomy with double-tract reconstruction and total gastrectomy for proximal early gastric cancer//BMC surgery. - 2019. - Т. 19. - N. 1. - С. 1 - 8.

100. Fein M. et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. - 2008.

101. Xiong J.J. et al. Roux-en-Y versus Billroth I reconstruction after distal gastrectomy for gastric cancer: a meta-analysis//World Journal of Gastroenterology: WJG. - 2013. - Т. 19. - N. 7. - С. 1124.

102. He L., Zhao Y. Is Roux-en-Y or Billroth-II reconstruction the preferred choice for gastric cancer patients undergoing distal gastrectomy when Billroth I reconstruction is not applicable? A meta-analysis//Medicine. - 2019. - Т. 98. - N. 48.

103. Nakamura M., Yamaue H. Reconstruction after proximal gastrectomy for gastric cancer in the upper third of the stomach: a review of the literature published from 2000 to 2014//Surgery today. - 2016. - Т. 46. - N. 5. - С. 517 - 527.

104. Трякин А.А., Бесова Н.С., Волков Н.М., Гладков О.А., Карасева В.В., Сакаева Д.Д., Федянин М.Ю. Общие принципы противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2025; 15(3s2-1.1): 38 - 53. https://doi.org/10.18027/2224-5057-2025-15-3s2-1.1-01

105. Cunningham D., Allum W.H., Stenning S.P. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11 - 20.

106. Ychou M., Pignon J.P., Lasser P. et al. Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (C) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNCLCC 94012 FFCD 9703 trial. Proc Am Soc Clin Oncol. 2006; 24(18S): Abstr. 4026.

107. Al-Batran S.E., Homann N., Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393(10184): 1948 - 57. doi: 10.1016/S0140-6736(18)32557 - 1.

108. Wang X. et al. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer//British Journal of Cancer. - 2016. - Т. 114. - N. 12. - С. 1326 - 1333.

109. Hu S.B. et al. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer//World Journal of Surgical Oncology. - 2019. - Т. 17. - N. 1. - С. 1 - 11 DOI: 10.1186/s12957-018-1534-z

110. Yu Y, Fang Y, Shen Z, et al. Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study.//Oncologist. 2019 Oct; 24(10): 1311 - e989. doi: 10.1634/theoncologist.2019-041.

111. Noh S.H., Park S.R., Yang H.K. et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 1389 - 96.

112. Cats A., Jansen E.P.M., van Grieken N.C.T. et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018; pii: S1470 - 2045 (18) 30132 - 3. doi: 10.1016/S1470-2045(18)30132-3.

113. Wong R, Anderson B, Bashir B, Bateman J, Chalchal H, Davies J, Dehmoobed A, Geller G, Ghose A, Gill S, Gordon V, Green S, Hebbard P, Iqbal M, Ji S, Karachiwala H, Kidane B, Kim C, Kosyachkova E, Krahn M, Krishnan T, Kristjanson M, Lee S, Lee-Ying R, Lelond S, Liu HW, Meyers D, Mulder K, Paul J, Planincic E. Report from the 25th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Gastric and Gastroesophageal Cancers, Winnipeg, Manitoba, 26 - 27 October 2023. Curr Oncol. 2024 Oct 7; 31(10): 5987 - 6006. doi: 10.3390/curroncol31100447. PMID: 39451751; PMCID: PMC11505746.

114. Al-Batran SE, Lorenzen S, Homann N, et al. Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: results from the DANTE trial of the Annals of Oncology F. Lordick et al. 1018 https://doi.org/10.1016/j.annonc.2022.07.004 Volume 33 - Issue 10 - 2022 German Gastric Group at the AIO and SAKK. Ann Oncol. 2021; 32(suppl_5): S1069.

115. Рисунок 39 T, Tougeron D, Piessen G, de la Рисунок 40 C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Рисунок 41 A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, Vernerey D, Henriques J, Lefevre JH, Svrcek M. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2023 Jan 10; 41(2): 255 - 265. doi: 10.1200/JCO.22.00686. Epub 2022 Aug 15. PMID: 35969830; PMCID: PMC9839243.

116. Hofheinz R, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group. Int J Cancer 2021. https://doi.org/10.1002/ijc.33696

117. Hofheinz RD, Haag GM, Ettrich TJ, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol 2020; 38(15_suppl): 4502.

118. Tong G, Li S, Lin L, et al. Trastuzumab with FLOT regimen for the perioperative treatment of resectable HER2 ю advanced gastric cancer: a retrospective study. Canc Manag Res 2020; 12: 2481e9. Epub 2020/04/21.

119. Rivera F, Izquierdo-Manuel M, Рисунок 42 P, Рисунок 43 de Castro E, Gallego J, Рисунок 44 ML, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021 Mar; 145: 158 - 167. doi: 10.1016/j.ejca.2020.12.005. Epub 2021 Jan 20. PMID: 33485079.

120. Smyth E.C., Wotherspoon A., Peckitt C. et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol 2017; 3(9): 1197 - 203. doi: 10.1001/jamaoncol.2016.6762.

121. Choi Y.Y., Kim H., Shin S.J. et al. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg 2019; 270(2): 309 - 16. doi: 10.1097/SLA.0000000000002803.

122. Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019; 37(35): 3392 - 3400

123. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesРисунок 45) Gastric Cancer Version 1.2025 - March 4, 2025-https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf

124. Stiekema J., Trip A.K., Jansen E.P. et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol 2014; 21: 1107 - 14.

125. Wang X, Shen Y, Zhu H, Zhao Y, Li Z, Qiu M, Li Q, Gou H, Yang Y, Cao D, Liu J, Yi C, Liao Z, Luo D, Bi F, Xu F. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. Gastric Cancer. 2016 Jan; 19(1): 245 - 54. doi: 10.1007/s10120-015-0461-8. Epub 2015 Jan 22. PMID: 25609451.

126. Smalley S.R., Benedetti J.K., Haller D.G. et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327 - 33.

127. Park SH, Sohn TS, Lim DH, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemotherapy in gastric cancer: Final report of the ARTIST trial, including survival and subset analyses. J Clin Oncol, published online before print January 5, 2015, doi: 10.1200/JCO.2014.58.3930.

128. Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK; ARTIST 2 investigators. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial*. Ann Oncol. 2021 Mar; 32(3): 368 - 374. doi: 10.1016/j.annonc.2020.11.017. Epub 2020 Dec 3. PMID: 33278599.

129. Wagner A.D., Grothe W., Haerting J. et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24(18): 2903 - 9.

130. Dank M., Zaluski J., Barone C. et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients, Journal of Clinical Oncology. 2005; Volume 23, Number 16_suppl. https://doi.org/10.1200/jco.2005.23.16_suppl.4003

131. Guimbaud R., Louvet C., Ries P. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Рисунок 46 Francophone de Рисунок 47 Digestive, Рисунок 48 Nationale des Centres de Lutte Contre le Cancer, and Groupe Рисунок 49 Multidisciplinaire en Oncologie) study. J Clin Oncol 2014; 32(31): 3520 - 6. doi: 10.1200/JCO.2013.54.1011.

132. Osumi H, Takahari D, Chin K, et a.l Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. Onco Targets Ther. 2018 Nov 23; 11: 8301 - 8307. doi: 10.2147/OTT.S184665.

133. Kang Y.-K., Kang W.-K., Shin D.-B., et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Annals of Oncology 2009. 20: 666 - 673. doi: 10.1093/annonc/mdn717

134. Ajani J.A., Moiseyenko V.M., Tjulandin S. et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007.1; 25(22): 3205 - 9.

135. Van Cutsem E., Boni C., Tabernero J. et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol 2015; 26(1): 149 - 56.

136. Shah M.A., Janjigian Y.Y., Stoller R. et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol 2015; 33(33): 3874 - 9.

137. Ochenduszko S. et al. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial//Medical Oncology. - 2015. - Т. 32. - N. 10. - С. 1 - 8.

138. Lee J., Kang W.K., Kwon J.M. etal. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.Ann Oncol 2007; 18(1): 88 - 92.

139. Obarevich E., Besova N., Trusilova E., Gorbunova V. Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (mFOLFIRINOX) as first-line therapy in advanced Her2-negative gastricorgastroesophageal adenocarcinoma (G/GEA). ESMO-18/Ann Clin Oncol 2018; 29 (Supp.8), p-viii227, abstr. 675P. (Ссылка: Annals of Oncology-29 (suppl_8) DOI: 10.1093/annonc/mdy282.059 License CC BY-NC-ND 4.0)

140. Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Aug 1; 6(8): 1231 - 1240. doi: 10.1001/jamaoncol.2020.2020. PMID: 32469386; PMCID: PMC7260693.

141. Van Cutsem E., Moiseyenko V.M., Tjulandin S., Majlis A., Constenla M., et al. Corrado Boni, Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. J Clin Oncol 24: 4991 - 4997. 2006. DOI: 10.1200/JCO.2006.06.8429233

142. Okines A.F., Asghar U., Cunningham D. et al. Rechallenge with platinum plus fluoropyrimidine +/- epirubicin in patients with oesophagogastric cancer. Oncology 2010; 79: 150 - 8.

143. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687 - 97.

144. Rivera F., Romero C., Jimenez Fonseca P. et al. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemotherapy and Pharmacology, 2019; 83: 1175 - 1181. https://doi.org/10.1007/s00280-019-03820-7

145. Soularue Рисунок 50., Cohen R., Tournigand C., et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study. Bull Cancer 2015; 102: pp 324 - 331.

146. Zaanan A, PalleJ, Soularue E et al. Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-EsophagealAdenocarcinoma: A Retrospective Multicenter AGEO Study. Targ Oncol 2018, V13, Issue 1, pp 107 - 112. https://doi.org/10.1007/s11523-017-0531-4.

147. Janjigian Y.Y., Shitara K., Moehler M., Garrido M., Salman P., Shen L., et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastrooesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Published Online June 5, 2021. https://doi.org/10.1016/S0140-6736(21)00797-2.

148. Rha SY, Oh DY, Рисунок 51 P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Рисунок 52 MG, Li J, Lowery MA, Рисунок 53 T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov; 24(11): 1181 - 1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Erratum in: Lancet Oncol. 2024 Dec; 25(12): e626. doi: 10.1016/S1470-2045(24)00650-8. PMID: 37875143.

149. Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, et al Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Jun 1; 7(6): 869 - 877. doi: 10.1001/jamaoncol.2021.0848. Erratum in: JAMA Oncol. 2021 Aug 1; 7(8): 1249. PMID: 33983395; PMCID: PMC8120440.

150. Inadomi K., Kusaba H., Matsushita Y., Tanaka R., Mitsugi K., Arimizu K., Hirano G., et al. Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer. Anticancer Research. 2017; 37 (5) 2663 - 2671. doi: 10.21873/anticanres.11614

151. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Рисунок 54 E. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008 Nov; 19(11): 1882 - 7. doi: 10.1093/annonc/mdn403. Epub 2008 Jul 31. PMID: 18669868

152. Li Q. et al. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy//Journal of Cancer Research and Clinical Oncology. - 2020. - Т. 146. - С. 287 - 295.

153. Hegewisch-Becker S. et al. Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): Findings from the German noninterventional observational study HerMES. - 2012.

154. Sun J, Pan SY, Chen QQ, Gao XP, Li W. Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2011 Aug; 31(8): 1458 - 60. Chinese. PMID: 21868346.

155. Dubreuil O, Zaanan A, Pellerin O et al. Trastuzumab re-introduction with FOLFIRI for treatment of HER2 Overexpression-advanced gastric Adenocarcinoma following failure of other Trastuzumab-based chemotherapy regimens. Case Rep Clin Med. 2015; 4: 131 - 6.

156. Nishikawa K., Tsuburaya A., Yoshikawa T., Takahashi M., Tanabe K., et al. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S 1 adjuvant therapy: XParTS I trial. Gastric Cancer (2018) 21: 811 - 818. https://doi.org/10.1007/s10120-018-0815-0

157. Бесова Н.С., Титова Т.А., Багрова С.Г., Обаревич Е.С., Горбунова В.А., Артамонова Е.В. Результаты применения трастузумаба в комбинации с различными режимами химиотерапии в первой линии лечения больных HER2 позитивным диссеминированным раком желудка. Медицинский совет. 2019. N 10, с. 120 - 127.

158. Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Feb; 23(2): 234 - 247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. PMID: 35030335.

159. Tabernero J., Bang Y., Van Cutsem E., Fuchs C., Janjigian Y., Bhagia P., Li K., Adelberg D., Qin S. KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology. 2020; Volume 31 - Issue S3; P-38: S101 - 102. Annals of Oncology Volume 31, Supplement 3, July 2020, Pages S101 - S102 DOI: https://doi.org/10.1016/j.annonc.2020.04.120.

160. Thuss-Patience P.C., Kretzschmar A., Bichev D. et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306 - 14. DOI: 10.1016/j.ejca.2011.06.002.

161. Ford H., Marshall A., Wadsley J. et al. Cougar-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. Lancet Oncol 2014; 15: 78 - 86. DOI: 10.1016/S1470-2045(13)70549-7.

162. Kang J.H., Lee S.I., Lim D.H. et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012; 30(13): 1513 - 8.

163. Roy A.C., Park S. R., Cunningham D.*, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Annals of Oncology 2013; 24: 1567 - 1573, doi: 10.1093/annonc/mdt002.

164. Hironaka S., Ueda S., Yasui H. et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013; 31(35): 4438 - 44.

165. Fuchs C.S., Tomasek J., Yong C.J. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383(9911): 31 - 9.

166. Di Lauro L., Fattoruso S.I., Giacinti L. et al. Second-line chemotherapy with FOLFIRI in patients with metastatic gastric cancer (MGC) not previously treated with fluoropyrimidines [abstract]. J Clin Oncol 2009; 27 (Suppl 15): Abstr. 454.

167. Wilke H., Muro K., Van Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014 Oct; 15(11): 1224 - 35.

168. Бесова Н.С., Титова Т.А., Строяковский Д.Л. и др. Результаты применения рамуцирумаба с иринотеканом и аналогами пиримидина во второй линии лечения больных диссеминированным раком желудка. Медсовет, 2019; 10: 100 - 9.

169. Klempner S.J., Maron S.B., Chase K. etal. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. The Oncologist 2019; 24: 475 - 82.

170. Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito YM, Sakata Y, Sakamoto N, Komatsu Y. Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603. Oncologist. 2022 Aug 5; 27(8): e642 - e649. doi: 10.1093/oncolo/oyac086. PMID: 35579511; PMCID: PMC9355819.

171. Satake H. et al. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane//Cancer chemotherapy and pharmacology. - 2018. - Т. 82. - N. 5. - С. 839 - 845.

172. Makiyama A, Sagara K, Kawada J, Kashiwada T, Hosokawa A, Horie Y, Satake H, Yamamoto Y, Tanioka H, Shinozaki K, et al. A randomized phase II study of weekly paclitaxel +/- trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT) J Clin Oncol. 2018; 36(15_suppl): 4011. doi: 10.1200/JCO.2018.36.15_suppl.4011.

173. Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017; 18(5): 640 - 653. doi: 10.1016/S1470-2045(17)30111-0.

174. Ter Veer E. et al. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis//Acta Oncologica. - 2018. - Т. 57. - N. 12. - С. 1599 - 1604.

175. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020 Jun 18; 382(25): 2419 - 2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. PMID: 32469182.

176. Ku GY, Di Bartolomeo M, Smyth E, et al.: 1205MO Updated analysis of DESTINYGastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. Ann Oncol. 2022; 33: S1100.

177. Fuchs CS, Рисунок 55 M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic C, Chung HC, Muro K, Van Cutsem E, Elme A, Thuss-Patience P, Chau I, Ohtsu A, Bhagia P, Wang A, Shih CS, Shitara K. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022 Jan; 25(1): 197 - 206. doi: 10.1007/s10120-021-01227-z. Epub 2021 Sep 1. PMID: 34468869; PMCID: PMC8732941.

178. Shitara K, Рисунок 56 M, Bang YJ, et al.; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018; 392(10142): 123 - 133. doi: 10.1016/S0140-6736(18)31257-1

179. Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, Keegan P, McKee AE, Pazdur R. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. Oncologist. 2019 Jan; 24(1): 103 - 109. doi: 10.1634/theoncologist.2018-0221. Epub 2018 Aug 17. PMID: 30120163; PMCID: PMC6324629.

180. Lala M, Ruosi Li T, Dinesh P. de Alwis, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. European Journal of Cancer. April 15, 2020. Vol. 131, P. 68 - 75

181. Samalin E, Afchain P, Рисунок 57 S, Abbas F, Romano O, Guimbaud R, et al. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Clin Res Hepatol Gastroenterol. 2011 Jan; 35(1): 48 - 54. doi: 10.1016/j.gcb.2010.06.010

182. Erdem GU, Bozkaya Y, Ozdemir NY, Demirci NS, Yazici O, Zengin N. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane. Bosn J Basic Med Sci. 2018 May 20; 18(2): 170 - 177. doi: 10.17305/bjbms.2017.2258. PMID: 28941466; PMCID: PMC5988536.

183. Burge ME, Smith D, Topham C, et al. A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer. 2006 May 8; 94(9): 1281 - 1286. Published online 2006 May 2. doi: 10.1038/sj.bjc.6603084.

184. Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2018 May; 19(5): 660 - 671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16. PMID: 29555258.

185. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 May 10; 4(5): e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10. Erratum in: JAMA Oncol. 2019 Apr 1; 5(4): 579. doi: 10.1001/jamaoncol.2019.0286. PMID: 29543932; PMCID: PMC5885175.

186. Kang Y.K., Boku N., Satoh T. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390: 2461 - 71.

187. Aoki M. et al. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan//Gastric Cancer. - 2023. - Т. 26. - N. 1. - С. 132 - 144.

188. Инструкция по применению лекарственного препарата "Опдиво" (Opdivo). Утверждена Минздравом России: ЛП-004026 от 19.09.2019. http://grls.rosminzdrav.ru/InstrImg/0001448198/%D0%9B%D0%9F-004026[2019]_0.pdf

189. Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol 2018; 36: 2836 - 44.

190. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, et al. (CheckMate 577). Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 Apr 1; 384(13): 1191 - 1203. doi: 10.1056/NEJMoa2032125. Erratum in: N Engl J Med. 2023 Feb 16; 388(7): 672. PMID: 33789008.

191. Rosati G., BilanciaD., Germano D., Dinota A., Romano R., Reggiardo G. & Manzion L.. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study. July 2007Annals of Oncology 18 Suppl 6(suppl 6): vi128 - 32 DOI: 10.1093/annonc/mdm

192. Kim Y.I., Choi I.J. Endoscopic management of tumor bleeding from inoperable gastric cancer.ClinEndosc 2015; 48(2): 121 - 7. doi: 10.5946/ce.2015.48.2.121.

193. Kawabata H, Hitomi M, Motoi S. Management of Bleeding from Unresectable Gastric Cancer. Biomedicines. 2019 Jul 24; 7(3): 54. doi: 10.3390/biomedicines7030054. PMID: 31344824; PMCID: PMC6784219.

194. Kondoh C., Shitara K., Nomura M. et al. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliat Care 2015; 14: 37. doi: 10.1186/s12904-015-0034-y.

195. Kim T.O., Kang D.H., Kim G.H. et al. Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. World J Gastroenterol 2007; 13(6): 916 - 20.

196. Endo S., Takiguchi S., Miyazaki Y. et al. Efficacy of endoscopic gastroduodenal stenting for gastric outlet obstruction due to unresectable advanced gastric cancer: a prospective multicenter study. J Surg Oncol 2014; 109(3): 208 - 12. doi: 10.1002/jso.23486.

197. Волков В.Е., Волков С.В. К вопросу о выборе метода паллиативных операций у больных раком желудка. Acta medica Eurasia, 2019, N 3, стр 7 - 14

198. Ly J., O'Grady G., Mittal A. et al. A systematic review of methods to palliate malignant gastric outlet obstruction. Surg Endosc 2010; 24(2): 290 - 7. doi: 10.1007/s00464-009-0577-1.

199. Issaka R.B., Shapiro D.M., Parikh N.D. et al. Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. Surg Endosc 2014(5): 1668 - 73. doi: 10.1007/s00464-013-3368-7.

200. Luther A., Gabriel J., Watson R.P., Francis N.K. The Impact of Total Body Prehabilitation on Post-Operative Outcomes After Major Abdominal Surgery: A Systematic Review. World J Surg. 2018; 42(9): 2781 - 91.

201. Владимирова Л.Ю., Гладков О.А., Королева И.А. и соавт. Тошнота и рвота. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 33 - 49. https://rosoncoweb.ru/standarts/?chapter=nausea_vomiting

202. Багрова С.Г., Атрушкевич В.Г., Борзов К.А. и соавт. Патология костной ткани. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 50 - 63. https://rosoncoweb.ru/standarts/?chapter=bone_pathology

203. Сомонова О.В., Антух Э.А., Варданян А.В. и соавт. Тромбоэмболические осложнения. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 218 - 232. https://rosoncoweb.ru/standarts/?chapter=thromboembolism

204. Сакаева Д.Д., Борисов К.Е., Булавина И.С. и соавт. Фебрильная нейтропения. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 64 - 73. https://rosoncoweb.ru/standarts/?chapter=febrile_neutropenia

205. Ткаченко П.Е., Маевская М.В., Ивашкин В.Т. Гепатотоксичность. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 2-06. https://rosoncoweb.ru/standarts/?chapter=hepatotoxicity

206. Виценя М.В., Полтавская М.Г., Потиевская В.И., Агеев Ф.Т. и соавт. Кардиоваскулярная токсичность. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 104 - 132. https://rosoncoweb.ru/standarts/?chapter=cardiovascular_toxicity

207. Королева И.А., Болотина Л.В., Гладков О.А. и соавт. Дерматологические реакции. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 133 - 175. https://rosoncoweb.ru/standarts/?chapter=dermatological_reactions

208. Громова Е.Г., Бирюкова Л.С., Курмуков И.А. и соавт. Нефротоксичность. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 199 - 217. https://rosoncoweb.ru/standarts/?chapter=nephrotoxicity

209. Новик А.В., Баллюзек М.Ф., Васильев Д.А. и соавт. Иммуноопосредованные нежелательные явления. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 271 - 329. https://rosoncoweb.ru/standarts/?chapter=immunerelated_adverse_events

210. Семиглазова Т.Ю., Беляк Н.П., Владимирова Л.Ю. и соавт. Мукозиты. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 352 - 364. https://rosoncoweb.ru/standarts/?chapter=mucositis

211. Орлова Р.В., Гладков О.А., Кутукова С.И. и соавт. Анемия. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 23 - 32. https://rosoncoweb.ru/standarts/?chapter=anemia

212. Yasufuku I, Nunobe S, Ida S, Kumagai K, Ohashi M, Hiki N, Sano T. Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Gastric Cancer. 2020 Mar; 23(2): 319 - 327. doi: 10.1007/s10120-019-00994-0. Epub 2019 Jul 26. PMID: 31350702.

213. Сытов А.В., Зузов С.А., Кукош М.Ю. и соавт. Синдром анорексии-кахексии. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 186 - 192. https://rosoncoweb.ru/standarts/?chapter=anorexia-cachexia

214. Исянгулова А.З., Шин А.Р., Петкау В.В. Центральный венозный доступ. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 387 - 400. https://rosoncoweb.ru/standarts/?chapter=central_venous_access

215. Когония Л.М., Новиков Г.А., Орлова Р.В. и соавт. Хронический болевой синдром у взрослых онкологических больных. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 245 - 270. https://rosoncoweb.ru/standarts/?chapter=chronic_pain_syndrome

216. Fujitani K, Yang H.K., Mizusawa J., et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016; 17(3): 309 - 318.

217. Namikawa T, Marui A, Yokota K, Kawanishi Y, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer. Langenbecks Arch Surg. 2022 Sep; 407(6): 2301 - 2308. doi: 10.1007/s00423-022-02543-3. Epub 2022 May 13. PMID: 35551466.

218. Granieri S, Altomare M, Bruno F, Paleino S, Bonomi A, Germini A, Facciorusso A, Fagnani D, Bovo G, Cotsoglou C. Surgical treatment of gastric cancer liver metastases: Systematic review and meta-analysis of long-term outcomes and prognostic factors. Crit Rev Oncol Hematol. 2021 Jul; 163: 103313. doi: 10.1016/j.critrevonc.2021.103313. Epub 2021 May 24. PMID: 34044098.

219. Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, Katai H, Watanabe M, Seto Y, Hoon Noh S, Kwang Yang H, Ji J, Baba H, Kitagawa Y, Morita S, Nishiyama M, Kodera Y; CONVO-GC-1 Study Group, Federation of Asian Clinical Oncology (FACO). International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2021 Oct 20; 6(2): 227 - 240. doi: 10.1002/ags3.12515. PMID: 35261948; PMCID: PMC8889854.

220. Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014 May; 101(6): 653 - 60. doi: 10.1002/bjs.9484. Epub 2014 Mar 25. PMID: 24668391.

221. Kroese TE, van Laarhoven HWM, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns CJ, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds J, Morganti AG, Rosati R, Castoro C, Cellini F, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen MI, Hulshof MCCM, van Dieren J, Vollebergh M, van Sandick JW, Jeene P, Muijs CT, Slingerland M, Voncken FEM, Hartgrink H, Creemers GJ, van der Sangen MJC, Nieuwenhuijzen G, Berbee M, Verheij M, Wijnhoven B, Beerepoot LV, Mohammad NH, Mook S, Ruurda JP, Kolodziejczyk P, Polkowski WP, Wyrwicz L, Alsina M, Pera M, Kanonnikoff TF, Cervantes A, Nilsson M, Monig S, Wagner AD, Guckenberger M, Griffiths EA, Smyth E, Hanna GB, Markar S, Chaudry MA, Hawkins MA, Cheong E, van Hillegersberg R, van Rossum PSN; OMEC collaborators. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer. 2023 May; 185: 28 - 39. doi: 10.1016/j.ejca.2023.02.015. Epub 2023 Feb 24. PMID: 36947929.

222. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013; 92: 715 - 27.

223. Swarm R.A., Abernethy A.P., Anghelescu D.L. et al. Adult cancer pain. J Natl Compr Canc Netw 2013; 11(8): 992 - 1022.

224. Jie B., Jiang Z.M., Nolan M.T. et al. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. Nutrition. 2012; 28: 1022 - 7.

225. Затевахин И.И., Лядов К.В., Пасечник И.Н. (eds.). Программа ускоренного выздоровления хирургических больных Fast track. М.; ГЭОТАР-Медиа, 2017. - 208 с.

226. Gemmill E.H., Humes D.J., Catton J.A. Systematic review of enhanced recovery after gastro-oesophageal cancer surgery. Ann R Coll Surg Engl 2015; 97: 173 - 9.

227. Feng F., Ji G., Li J.P. et al. Fast-track surgery could improve postoperative recovery in radical total gastrectomy patients. World J Gastroenterol 2013; 19(23): 3642 - 8.

228. Almeida E.P.M., Almeida J.P., Landoni G. et al. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial. Brit J Anaesth 2017; 119(5): 900 - 7.

229. Jo DH, Jeong O, Sun JW, Jeong MR, Ryu SY, Park YK. Feasibility study of early oral intake after gastrectomy for gastric carcinoma. J Gastric Cancer. 2011 Jun; 11(2): 101 - 8.

230. Mortensen K, Nilsson M, Slim K, et al; Enhanced Recovery After Surgery (ERASРисунок 58) Group. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERASРисунок 59) Society recommendations. Br J Surg. 2014 Sep; 101(10): 1209 - 29.

231. Рисунок 60 E. et al. Feeding Jejunostomy after esophagectomy cannot be routinely recommended. Analysis of nutritional benefits and catheter-related complications. Am J Surg 217; 1: 114 - 20.

232. Sun H.B., Li Y., Liu X.B. et al. Early Oral Feeding Following McKeown Minimally Invasive Esophagectomy: An Open-label, Randomized, Controlled, Non-inferiority Trial. Ann Surg 2018; 267(3): 435 - 42.

233. Steenhagen E., van Vulpen J.K., van Hillegersberg R. et al. Nutrition in peri-operative esophageal cancer management. Expert Review of Gastroenterology Hepatology 2017; 11(7): 663 - 72.

234. Shin K.Y., Guo Y., Konzen B. et al. In patient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011; 90(5): 63 - 8.

235. Bourke L., Homer K.E., Thaha M.A. et al. Interventions to improve exercise behavior in sedentary people living with and beyond cancer: a systematic review. Br J Cancer 2014; 110: 831 - 41.

236. Muscaritoli M., Arends J., Bachmann P., et al. ESPEN practical guideline: Clinical Nutrition in cancer//Clin Nutr. 2021. Vol. 40, N 5. P. 2898 - 2913. doi: 10.1016/j.clnu.2021.02.005.

237. Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open. 2021; 6(3): 100092. doi: 10.1016/j.esmoop.2021.100092.

238. Бриш Н.А., Семиглазова Т.Ю., Карачун А.М., соавт. Влияние коррекции нутритивной недостаточности на эффективность неоадъювантной химиотерапии у больных местно-распространенным раком желудка. Современная Онкология. 2021; 23(3): 519 - 524. DOI: 10.26442/18151434.2021.3.201075.

239. Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3: 961 - 8.

240. Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018; 26: 1019 - 28.

241. Dennett A.M., Peiris C.L., Shields N. et al. Moderate-intensity exercise reduces fatigue and improves mobility in cancer survivors: a systematic review and meta-regression. J Physio-ther 2016; 62(2): 68 - 82.

242. Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44: 1289 - 304.

243. Tomanovic Vujadinovic S, Ilic N, Selakovic I, et al. TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients. Medicina (Kaunas). 2022 6; 58(10): 1405. doi: 10.3390/medicina58101405.

244. Rick O, von Hehn U, Mikus E, Dertinger H, Geiger G. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics. 2017; 38(2): 85 - 94. doi: 10.1002/bem.22005.

245. Lopez G, Eng C, Overman M, Ramirez D, Liu W, Beinhorn C, et al. A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy.//Sci Rep. 2022; 12(1): 19023. doi: 10.1038/s41598-022-23372-w

246. Teng C, Egger S, Blinman PL, Vardy JL. Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial. Support Care Cancer. 2022; 31(1): 52. doi: 10.1007/s00520-022-07463-y.

247. Заридзе Д.Г. Профилактика - наиболее эффективное направление противораковой борьбы. - Практическая онкология. 2016: 17; N 4: 213 - 227.

248. Huang RJ, Epplein M, Hamashima C, Choi IJ, Lee E, Deapen D, Woo Y, Tran T, Shah SC, Inadomi JM, Greenwald DA, Hwang JH. An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. Clin Gastroenterol Hepatol. 2022 Oct; 20(10): 2218 - 2228.e2. doi: 10.1016/j.cgh.2021.09.039. Epub 2021 Oct 6. PMID: 34624563; PMCID: PMC8983795

249. Сытов А.В., Зузов С.А., Кукош М.Ю. и соавт. Нутритивная поддержка. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 176 - 185. https://rosoncoweb.ru/standarts/?chapter=nutritional_support

250. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019 May; 22(3): 435 - 445. doi: 10.1007/s10120-018-0876-0. Epub 2018 Sep 11. PMID: 30206731

251. Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, Chen YR, Chuang SL, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Lin MW, Wu MS, Lin JT, Chan CC, Graham DY, Chen HH, Lee YC. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021 Feb; 70(2): 243 - 250. doi: 10.1136/gutjnl-2020-322200. Epub 2020 Aug 13. PMID: 32792335; PMCID: PMC7815911.

252. Пиманов С.И., Макаренко Е.В. Обновленные рекомендации Маастрихт VI/Флорентийского консенсуса по лечению инфекции Helicobacter pylori. Consilium Medicum. 2022; 24(12): 851 - 859. DOI: 10.26442/20751753.2022.12.202045.

253. Ивашкин В.Т., Маев И.В., Лапина Т.Л., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации "Эндоскопическое общество РЭНДО" по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2021; 31(4): 70 - 9 [Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2021; 31(4): 70 - 99 (in Russian)]. DOI: 10.22416/1382-4376-2021-31-4-70-99

254. Blair VR, McLeod M, Carneiro F, Coit DG, D'Addario JL, van Dieren JM, Harris KL, Hoogerbrugge N, Oliveira C, van der Post RS, Arnold J, Benusiglio PR, Bisseling TM, Boussioutas A, Cats A, Charlton A, Schreiber KEC, Davis JL, Pietro MD, Fitzgerald RC, Ford JM, Gamet K, Gullo I, Hardwick RH, Huntsman DG, Kaurah P, Kupfer SS, Latchford A, Mansfield PF, Nakajima T, Parry S, Rossaak J, Sugimura H, Svrcek M, Tischkowitz M, Ushijima T, Yamada H, Yang HK, Claydon A, Figueiredo J, Paringatai K, Seruca R, Bougen-Zhukov N, Brew T, Busija S, Carneiro P, DeGregorio L, Fisher H, Gardner E, Godwin TD, Holm KN, Humar B, Lintott CJ, Monroe EC, Muller MD, Norero E, Nouri Y, Paredes J, Sanches JM, Schulpen E, Ribeiro AS, Sporle A, Whitworth J, Zhang L, Reeve AE, Guilford P. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020 Aug; 21(8): e386 - e397. doi: 10.1016/S1470-2045(20)30219-9. PMID: 32758476; PMCID: PMC7116190.

255. Monahan KJ, Hopkins L. Diagnosis and Management of Hereditary Gastric Cancer. Recent Results Cancer Res. 2016; 205: 45 - 60. doi: 10.1007/978-3-319-29998-3_4. PMID: 27075348.

256. Chen Y., Kingham K., Ford J.M. et al. A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. Ann Surg Oncol 18, 2594 - 2598 (2011). https://doi.org/10.1245/s10434-011-1648-9.

257. Vos EL, Salo-Mullen EE, Tang LH et al. Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surg. 2020 Nov 1; 155(11): 1050 - 1057. doi: 10.1001/jamasurg.2020.3356.

258. Strong VE, Gholami S, Shah MA et al. Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. Ann Surg. 2017 Dec; 266(6): 1006 - 1012. doi: 10.1097/SLA.0000000000002030.

259. Roviello, G., Rodriquenz, M. G., Aprile, G., D'Angelo, A., Roviello, F., Nobili, S., et al.. (2021). Maintenance in gastric cancer: New life for an old issue? Critical Reviews in Oncology/Hematology, 2021; 160(1), 103307. doi: 10.1016/j.critrevonc.2021.103307

260. Park SR, Kim MJ, Nam BH, Kim CG, Lee JY, Cho SJ, Kong SY, Park YI. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. Eur J Cancer. 2017 Sep; 83: 32 - 42. doi: 10.1016/j.ejca.2017.06.008. Epub 2017 Jul 14. PMID: 28711577.

261. Cunningham D., Fong C.Y.K., Peckitt C., Anandappa G., Davidson M., Patel B., Turner A., et al. Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study. Journal of Clinical Oncology 38(4_suppl): 282 - 282. DOI: 10.1200/JCO.2020.38.4_suppl.282

262. Lee GJ, Kim H, Cho SS, Park HS, An HJ, Woo IS, Byun JH, Hong JH, Ko YH, Sun S, Won HS, Jin JY, Park JC, Kim IH, Roh SY, Shim BY. A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation. J Gastric Cancer. 2023 Apr; 23(2): 315 - 327. doi: 10.5230/jgc.2023.23.e16. PMID: 37129155; PMCID: PMC10154142.

263. Рисунок 61 A, Carmona-Bayonas A, Gallego J, Lacalle A, Рисунок 62 R, Cano JM, Рисунок 63 I, Custodio A, Рисунок 64 de Castro E, Рисунок 65 A, Iglesia L, Reguera P, Visa L, Azkarate A, Рисунок 66 M, Mangas M, Рисунок 67 ML, Рисунок 68 A, Asensio E, Ramchandani A, Рисунок 69 A, Hurtado A, Рисунок 70 P, Garrido M, Рисунок 71 R, Serrano R, Рисунок 72 P; AGAMENON Study Group. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. Clin Transl Oncol. 2020 May; 22(5): 734 - 750. doi: 10.1007/s12094-019-02183-y. Epub 2019 Aug 5. PMID: 31385226.

264. Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev, 2021 Nov 16; 11(11): CD012775

265. Navari R.M., Gray S.E., Kerr A.C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9(5): 188 - 95

266. NCCN Guidelines. Prevention and Treatment of Cancer-Related Infections. v. 1, 2021. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.

267. Yoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda, et al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutro-penia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015 Apr; 23(4): 1137 - 43.

268. Mical Paul, Dafna Yahav, Abigail Fraser, Leonard Leibovici. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized con-trolled trials. Journal of Antimicrobial Chemotherapy, Volume 57, Issue 2, February 2006, Pages 176 - 189.

269. Shah N., Andrews J., Goodnough L.T. Transfusions for anemia in adult and pediatric patients with malignancies//Blood Rev. Churchill Livingstone, 2015. Vol. 29, No 5. P. 291 - 299;

270. Bohlius J. et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update//J. Clin. Oncol. American Society of Clinical Oncology, 2019. Vol. 37, No 15. P. 1336 - 1351.

271. S. Rosello, I. Blasco, L. Рисунок 73 Fabregat, A. Cervantes, K. Jordan. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Annals of Oncology 28 (Supplement 4): iv100 - iv118, 2017

272. Орлова Р.В., Жабина А.С., Иванова А.К. и соавт. Инфузионные реакции. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 365 - 386. https://rosoncoweb.ru/standarts/?chapter=infusion_reactions

273. Орлова Е.В., Грабовская О.В., Белоусова Т.А., Севидова Л.Ю., Багирова А.А. Синдром "hand-foot" у онкологических больных на фоне химиотерапии. Российский журнал кожных и венерических болезней. 2015; 18(5): 21 - 26.

274. Королева И.А., Болотина Л.В., Гладков О.А. и соавт. Дерматологические реакции. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 133 - 175. https://rosoncoweb.ru/standarts/?chapter=dermatological_reactions

275. B Vincenzi, A Russo, A Terenzio, et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol 2018 Oct; 130: 70 - 77.

276. Devika Remash, David S Prince, Catriona McKenzie, et al. Immune checkpoint in-hibitor-related hepatotoxicity: A review. World J Gastroenterol 2021 Aug 28; 27(32): 5376 - 5391.

277. Perazella, Mark A. Onco-Nephrology. Renal Toxicities of Chemotherapeutic Agents Clinical Journal of the American Society of Nephrology, 2012 October, 7(10): p 1713 - 1721.

278. Han Li, Jinsheng Xu, Yaling Bai, Shenglei Zhang, Meijuan Cheng, Jingjing Jin. Ne-phrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Investigational New Drugs, 2021, Volume 39, pages 860 - 870.

279. Songtao Li, Xiuyun He, Linjie Ruan, Ting Ye, Yulong Wen, Zhihua Song, Siying Hu, Yu Chen, Bo Peng, Shijie Li. Protective Effect of Mannitol on Cisplatin-Induced Ne-phrotoxicity: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11, Published online 2021 Dec 16.

280. Albakri, Aref. Systolic heart failure: A review of clinical status and metaanalysis of diagnosis and clinical management methods. Trends in Res, 2018, 1(4), doi: 10.15761/TR.1000124.

281. Jasper Tromp, Wouter Ouwerkerk, Dirk J. van Veldhuisen, et al. A Systematic Re-view and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol HF. Dec 08, 2021.

282. Kashif Kalam, Thomas H. Marwick. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer 2013 Sep; 49(13): 2900 - 9.

283. Sonal Krishan, Nalinda Panditaratne, Rajeev Verma, Roderick Robertson. Incremental value of CT venography combined with pulmonary CT angiography for the detection of thromboembolic disease: systematic review and meta-analysis. AJR Am J Roentgenol 2011; 196(5): 1065 - 72.

284. Chinthaka B Samaranayake, James Anderson, Colm McCabe, Syeda Farah Zahir, John W Upham, Gregory Keir, Direct oral anticoagulants for cancer-associated venous thromboembo-lisms: a systematic review and network meta-analysis, Intern Med J, 2022 Feb; 52(2): 272 - 281.

285. William Knoll, Nathan Fergusson, Victoria Ivankovic, Tzu-Fei Wang, Lucia Caiano, Rebecca Auer, Marc Carrier, Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature, Thromb Res, 2021 Aug: 204: 114 - 122.

286. NCCN guidelines.. Management of Immunotherapy-Related Toxicities. Version https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.

287. Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. Journal for ImmunoTherapy of Cancer, 2018, article number: 103.

288. Guillermo De Velasco, Youjin Je, Dominick Рисунок 74, Mark M. Awad, Patrick A. Ott, Raphael B. Moreira, Fabio Schutz, Joaquim Bellmunt, Guru P. Sonpavde, F. Stephen Hodi, Toni K. Choueiri. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res, 2017, 5 (4): 312 - 318

289. Chaoyang Chen, Ruoming Li, Ting Yang. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials. Clinical Therapeutics 2020, 42(8): 1494 - 1507.e1.

290. Paola Alberti, Alessandro Salvalaggio, Andreas A. Argyriou, Jordi Bruna, Andrea Visentin, Guido Cavaletti, and Chiara Briani. Neurological Complications of Conventional and Novel Anticancer Treatments. Cancers (Basel). 2022 Dec; 14(24): 6088.

291. Латипова Д.Х., Андреев В.В., Маслова Д.А. и соавт. Неврологические осложнения. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 410 - 425. https://rosoncoweb.ru/standarts/?chapter=neurological_complication

292. Fangyuan Zhang, Aomei Shen, Yinghui Jin, Wanmin Qiang. The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews. BMC Complement Altern Med. 2018; 18: 236.

293. Khalis Mustafayev, Harrys Torres. Narrative review. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clinical Microbiology and Infection. Volume 28, Issue 10, October 2022, Pages 1321 - 1327.

294. Феоктистова П.С., Винницкая Е.В., Нурмухаметова Е.А., Тихонов И.Н. Реактивация/обострение хронических вирусных гепатитов во время противоопухолевой терапии. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 401 - 409. https://rosoncoweb.ru/standarts/?chapter=chronic_viral_hepatitis

295. Firas Y Kreidieh, Hiba A Moukadem, and Nagi S El Saghir Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol. 2016 Feb 10; 7(1): 87 - 97.

296. Буйденок Ю.В., Обухова О.А. Экстравазация противоопухолевых препаратов. Клинические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2025; 15(3s2): 233 - 244. https://rosoncoweb.ru/standarts/?chapter=extravasation_antitumor_drugs

297. Margaux Evenepoel, Vincent Haenen, Tom De Baerdemaecker, Mira Meeus, Nele Devoogdt, Lore Dams, Sophie Van Dijck, Elien Van der Gucht, An De Groef. Pain Prevalence During Cancer Treatment: A Systematic Review and Meta-Analysis. Pain Symptom Manage, 2022 Mar; 63(3): e317 - e335

298. Barbosa-Matos R, Рисунок 75 L, Schrader K, Oliveira C. Diffuse Gastric and Lobular Breast Cancer Syndrome. 2002 Nov 4 [updated 2024 Oct 10]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviewsРисунок 76 [Internet]. Seattle (WA): University of Washington, Seattle; 1993 - 2025.

299. Liu YH, Meng R, Zhu B, Zhan QQ, Yang X, Ding GY, Jia CL, Xu WG. A meta-analysis of the efficacy of Roux-en-Y anastomosis and jejunal interposition after total gastrectomy. World J Surg Oncol. 2023 Apr 25; 21(1): 136. doi: 10.1186/s12957-023-03002-z.

300. Yang YS, Chen LQ, Yan XX, Liu YL. Preservation versus non-preservation of the duodenal passage following total gastrectomy: a systematic review. J Gastrointest Surg. 2013 May; 17(5): 877 - 86. doi: 10.1007/s11605-013-2174-9.

301. Pinto SOSA, Pereira MA, Ribeiro Junior U, D'Albuquerque LAC, Ramos MFKP. PALLIATIVE GASTRECTOMY VERSUS GASTRIC BYPASS FOR SYMPTOMATIC CLINICAL STAGE IV GASTRIC CANCER: A PROPENSITY SCORE MATCHING ANALYSIS. Arq Bras Cir Dig. 2024 Feb 5; 36: e1790. doi: 10.1590/0102-672020230072e1790

302. Gingrich AA, Flojo RB, Walsh A, Olson J, Hanson D, Bateni SB, Gholami S, Kirane AR. Are Palliative Interventions Worth the Risk in Advanced Gastric Cancer? A Systematic Review. J Clin Med. 2024 Sep 28; 13(19): 5809. doi: 10.3390/jcm13195809.

303. Mahar AL, Brar SS, Coburn NG, Law C, Helyer LK. Surgical management of gastric perforation in the setting of gastric cancer. Gastric Cancer. 2012 Sep; 15 Suppl 1: S146 - 52. doi: 10.1007/s10120-011-0095-4.

304. D.E. Peterson, R.-J. Bensadoun, F. Roila. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Annals of Oncology 21 (Supplement 5): v261 - v265, 2010.

305. C.D. Arteaga и R. Wadhwa, "Gastric Polyp", в StatPearls, Treasure Island (FL): StatPearls Publishing, 2025. Просмотрено: 9 июль 2025 г. [Онлайн]. Доступно на: http://www.ncbi.nlm.nih.gov/books/NBK560704/

306. D. Early, "Diagnosis and approach to gastric polyps", Gastrointest. Endosc., т. 98, вып. 4, сс. 618 - 620, окт. 2023, doi: 10.1016/j.gie.2023.02.028

307. H. Yacoub и др., "Gastric polyps: a 10-year analysis of 18,496 upper endoscopies", BMC Gastroenterol., т. 22, вып. 1, с. 70, фев. 2022, doi: 10.1186/s12876-022-02154-8.

308. ASGE Standards of Practice Committee и др., "The role of endoscopy in the management of premalignant and malignant conditions of the stomach", Gastrointest. Endosc., т. 82, вып. 1, сс. 1 - 8, июл. 2015, doi: 10.1016/j.gie.2015.03.1967.

309. M. Ali, L. Srour, M. Bitar, K. Karam, I.I. El Hajj, и E. Fiani, "Current Guidelines and Advances in the Management of Fundic Gland Polyps", J. Gastroenterol. Hepatol., т. 40, вып. 6, сс. 1374 - 1380, июн. 2025, doi: 10.1111/jgh.16972.

310. D. Costa, D. Ramai, и A. Tringali, "Novel classification of gastric polyps: The good, the bad and the ugly", World J. Gastroenterol., т. 30, вып. 31, сс. 3640 - 3653, авг. 2024, doi: 10.3748/wjg.v30.i31.3640.

311. A.K. Dutta и др., "Image-enhanced endoscopy for real-time differentiation between hyperplastic and fundic gland polyps in the stomach", Indian J. Gastroenterol., т. 41, вып. 6, сс. 599 - 609, дек. 2022, doi: 10.1007/s12664-022-01278-9.

312. J.H. Cho, C.M. Shin, H. Yoon, Y.S. Park, N. Kim, и D.H. Lee, "Comparison of endoscopic treatments for small gastric adenomas", Surg. Endosc., т. 36, вып. 6, сс. 3920 - 3931, июн. 2022, doi: 10.1007/s00464-021-08710-9.

313. S. Vos, R.S. van der Post, и L.A.A. Brosens, "Gastric Epithelial Polyps: When to Ponder, When to Panic", Surg. Pathol. Clin., т. 13, вып. 3, сс. 431 - 452, сен. 2020, doi: 10.1016/j.path.2020.05.004.

314. G. Zhao, M. Xue, Y. Hu, S. Lai, S. Chen, и L. Wang, "How Commonly Is the Diagnosis of Gastric Low Grade Dysplasia Upgraded following Endoscopic Resection? A Meta-Analysis", PLOS ONE, т. 10, вып. 7, с. e0132699, 2015, doi: 10.1371/journal.pone.0132699

315. H. Waldum и R. Fossmark, "Gastritis, Gastric Polyps and Gastric Cancer", Int. J. Mol. Sci., т. 22, вып. 12, с. 6548, июн. 2021, doi: 10.3390/ijms22126548.

316. Y. Kim и др., "Risk factors associated with recurrence of gastric hyperplastic polyps: a single-center, long-term, retrospective cohort study", Surg. Endosc., т. 37, вып. 10, сс. 7563 - 7572, окт. 2023, doi: 10.1007/s00464-023-10194-8.

317. J. Paszkowski, P. Samborski, M. Kucharski, J. Рисунок 77, T. Banasiewicz, и A. Рисунок 78, "Endoscopic Surveillance and Treatment of Upper GI Tract Lesions in Patients with Familial Adenomatous Polyposis-A New Perspective on an Old Disease", Genes, т. 13, вып. 12, с. 2329, дек. 2022, doi: 10.3390/genes13122329.

318. Janjigian, Y.Y., Kawazoe A., Bai Y., Xu J., Lonardi S., Metges J-P., Yanez P.E. et al. Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma. Annals of Oncology. 2024; Volume 35, S877 - S878.

319. Семиглазова Т.Ю., Алексеева Ю.В., Бесова Н.С. и соавт. Особенности назначения противоопухолевого лекарственного лечения у пациентов старших возрастных групп. Клинические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2025; 15(3s2): 54 - 72. https://doi.org/10.18027/2224-5057-2025-15-3s2-1.1-02

320. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med. 2025 Jun 1. doi: 10.1056/NEJMoa2503701. Epub ahead of print. PMID: 40454643.

321. Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024 Aug; 9(8): 705 - 717. doi: 10.1016/S2468-1253(24)00156-0. Epub 2024 Jun 18. Erratum in: Lancet Gastroenterol Hepatol. 2025 Apr; 10(4): e7. doi: 10.1016/S2468-1253(25)00047-0. PMID: 38906161.

322. PD-L1 expression and immune checkpoint inhibitors for the treatment of HER2 negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma Oncologic Drugs Advisory Committee (ODAC) Meeting September 26, 2024. https://www.fda.gov/media/182210/download

323. Fei S, Lu Y, Chen J, Qi J, Wu W, Wang B, Han Y, Wang K, Han X, Zhou H, Wang J, Chen J. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis. Chemotherapy. 2023; 68(4): 197 - 209. doi: 10.1159/000531457.

324. Beshr MS, Beshr IA, Al Hayek M, Alfaqaih SM, Abuajamieh M, Basheer E, Wali AK, Ekreer M, Chenfouh I, Khashan A, Hassan ET, Elnaami SM, Elhadi M. PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis. Clin Oncol (R Coll Radiol). 2024 Dec; 36(12): 797 - 808. doi: 10.1016/j.clon.2024.09.007. Epub 2024 Sep 21. PMID: 39384455.

325. Hairoula M, Wei Y, Muhetaer K, Ma X, Cao L, Gao Y, Qu C, Yi W, Zhang L. Efficacy and safety of PD-1 inhibitors in combination with chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction cancer across subgroups: A comprehensive systematic review and meta-analysis. Medicine (Baltimore). 2025 Aug 15; 104(33): e41751. doi: 10.1097/MD.0000000000041751. PMID: 40826733; PMCID: PMC12366957.

326. Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Рисунок 79 Рисунок 80, Fujitani K, Beretta GD, Cutsem EV, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov; 19(11): 1437 - 1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Erratum in: Lancet Oncol. 2018 Dec; 19(12): e668. doi: 10.1016/S1470-2045(18)30843-X. PMID: 30355453.

327. Ивашкин В.Т., Лапина Т.Л., Маев И.В., Драпкина О.М., Козлов Р.С., Шептулин А.А., Трухманов А.С., Абдулхаков С.Р., Алексеева О.П., Алексеенко С.А., Андреев Д.Н., Бордин Д.С., Дехнич Н.Н., Кляритская И.Л., Корочанская Н.В., Осипенко М.Ф., Полуэктова Е.А., Сарсенбаева А.С., Симаненков В.И., Ткачев А.В., Ульянин А.И., Хлынов И.Б., Цуканов В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022; 32(6): 72 - 93. https://doi.org/10.22416/1382-4376-2022-32-6-72-93

328. Ford A.C., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020; 69(12): 2113 - 21. DOI: 10.1136/gutjnl-2020-320839

329. Choi I.J., Kook M.C., Kim Y.I., Cho S.-J., Lee J.Y., Kim C.G., et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018; 378(12): 1085 - 95. DOI: 10.1056/NEJMoa1708423

330. Bang C.S., Baik G.H., Shin I.S., Kim J.B., Suk K.T., Yoon J.H., et al. Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. J Korean Med Sci. 2015; 30(6): 749 - 56.

331. Jung D.H., Kim J.H., Chung H.S., Park J.C., Shin S.K., Lee S.K., et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoSOne. 2015; 10(4): e0124725. DOI: 10.1371/journal.pone.0124725

332. Kim M, Seo AN. Molecular Pathology of Gastric Cancer. J Gastric Cancer. 2022 Oct; 22(4): 273 - 305. https://doi.org/10.5230/jgc.2022.22.e35

333. Пайчадзе А.А., Миронова Д.Ю., Рябов А.Б., Колобаев И.В., Белохвостова А.С., Смоленов Е.И., Каприн А.Д. Возможности иммунотерапии в лечении местнораспространенного рака желудка и кардиоэзофагеального перехода. Онкология. Журнал им. П.А. Герцена. 2026; 15(3): 91 - 98.

334. Оганян К.А., Мусаелян А.А., Лапин С.В. и др. Молекулярные маркеры ответа на периоперационную химиотерапию при местно-распространенном раке желудка. Успехи молекулярной онкологии 2023; 10(1): 40 - 8. DOI: 10.17650/2313-805X-2023-10-1-40-48

335. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesРисунок 81). Gastric Cancer. Version 3.2026. [Internet]. Plymouth Meeting (PA): NCCN; 2026 [cited 2026 Jun 9]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434

336. Ассоциация онкологов России, Общероссийская общественная организация "Российское общество клинической онкологии", Общероссийская общественная организация "Российское общество онкомаммологов" Клинические рекомендации "Рак молочной железы", 2021 г. URL: https://cr.minzdrav.gov.ru/preview-cr/379_4